A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength

Simply Wall St.06-04

AdvertisementEvent context and recent stock move BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2640688156?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-04 17:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640688156","market":"hk","top_or_hot":-1,"title":"A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementEvent context and recent stock move BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-recen-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-04 17:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-recen-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementEvent context and recent stock move BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-recen-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3B42.SGD","symbol_name":"Legg Mason ClearBridge - Value A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-recen-1","article_id":"2640688156","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bmrn/biomarin-pharmaceutical/news/a-look-at-biomarin-pharmaceutical-bmrn-valuation-after-recen-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640688156","pubTimestamp":1780565950,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Event context and recent stock move\nBioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, while longer term returns remain weaker.\nSee our latest analysis for BioMarin Pharmaceutical.\nThe latest move sits against a mixed backdrop, with the share price down about 10% over the past three months and year to date, while the 1-year total shareholder return is also slightly negative. This pattern...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4566":"资本集团","BMRN.AU":"Ballymore Resources Ltd","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","BK4139":"生物科技","BMRN":"拜玛林制药","BK7095":"多种金属与采矿","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD"},"translate_title":"近期股价走强后拜玛林制药(BMRN)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":1.5,"BMRN.AU":1.5},"content_text":"AdvertisementEvent context and recent stock move BioMarin Pharmaceutical (BMRN) has drawn investor attention after recent trading, with the stock up about 2.5% on the day and 4.4% over the past week, while longer term returns remain weaker. See our latest analysis for BioMarin Pharmaceutical. The latest move sits against a mixed backdrop, with the share price down about 10% over the past three months and year to date, while the 1-year total shareholder return is also slightly negative. This pattern suggests recent buying interest is nudging momentum higher in the short term, even as longer term holders have seen weaker outcomes and may still be reassessing growth potential and risk. If you are comparing BioMarin with other healthcare opportunities, this could be a useful moment to scan for niche leaders using the 39 healthcare AI stocks With BioMarin’s share price weaker over 1 and 3 years, but recent revenue and net income growth on the board, plus a market value of about US$10.3b, is this a mispriced rare disease specialist or is future growth already reflected? Most Popular Narrative: 39.2% Undervalued BioMarin’s most followed narrative pegs fair value at $89.96 per share versus the last close at $54.66, framing a sizeable implied upside that hinges on a specific view of future growth and profitability.  Analysts expect earnings to reach $1.3 billion (and earnings per share of $6.6) by about May 2029, up from $268.7 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.1 billion in earnings, and the most bearish expecting $746.2 million.  Read the complete narrative. Curious what kind of revenue trajectory and margin profile would justify that jump in earnings, all discounted at 7.3% and paired with a lower future P/E multiple. Result: Fair Value of $89.96 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there are clear pressure points, including heavier R&D and commercial spending, as well as tighter pricing or reimbursement decisions that could leave earnings and margins below consensus paths. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Another lens on valuation The popular fair value narrative leans on earnings forecasts and a future P/E, but the current numbers tell a tighter story. BioMarin trades on a P/E of 39.3x, versus 15.9x for the US biotech industry, 19.5x for peers and a fair ratio of 26x, which points to valuation risk rather than a clear bargain. How comfortable are you paying a premium multiple when growth, margins and execution are still being debated? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BMRN P/E Ratio as at Jun 2026Next Steps Feeling torn between the bullish fair value case and the premium P/E? This is the point to look under the hood yourself, weigh both the concern around risks and the optimism on potential rewards, and then decide how that balance sits with your own approach using these 2 key rewards and 3 important warning signs Looking for more investment ideas? If BioMarin has sharpened your thinking, do not stop here. Broaden your watchlist and pressure test your approach against other stocks with different strengths.  Target steadier compounding by scanning companies with resilient balance sheets and consistent fundamentals using the solid balance sheet and fundamentals stocks screener (47 results). Hunt for quality at a discount by checking companies that screen well on valuation and fundamentals through the 47 high quality undervalued stocks. Spot potential future standouts before the crowd by running the screener containing 22 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BioMarin Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640688156","isCrawlerRequest":true}